Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sichuan Huiyu Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, primarily focused on the Chinese market. The company differentiates itself through its extensive portfolio of over 100 products, including key therapeutic areas such as oncology and cardiovascular diseases, which are supported by its strong R&D capabilities.
Huiyu generates revenue through the sale of generic and specialty drugs, leveraging its strong R&D to maintain a competitive edge in pricing and product differentiation. The company benefits from a relatively low-cost structure due to its efficient manufacturing processes and a favorable regulatory environment in China.
Regulatory approvals for new drugs in China
Changes in pricing policies for generic drugs
Market share shifts in key therapeutic areas
Partnerships or collaborations with larger pharmaceutical firms
Regulatory changes in drug pricing and approval processes
Technological disruption in drug development and manufacturing
Intense competition from both domestic and international pharmaceutical companies
Potential for price erosion in the generic drug market
Low net margins indicate potential liquidity issues if operating losses continue
Rising operational costs could further strain profitability
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand for non-essential drugs may decline during recessions.
Rising interest rates could increase the company's financing costs, impacting its ability to invest in R&D and expansion, which may lead to lower valuation multiples.
minimal - The company has a low debt-to-equity ratio of 0.19, indicating limited reliance on external financing.
value - Investors may be drawn to the stock for its low valuation metrics despite current operational challenges.
moderate - The stock has shown historical volatility, with a beta of approximately 1.2.
